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Abstract 
Systemic lupus erythematosus is frequently associated with antiphospholipid syndrome. Patients 
with lupus-antiphospholipid syndrome are characterized by recurrent arterial/venous thrombosis, 
miscarriages, and persistent presence of autoantibodies against phospholipid-binding proteins, such 
as β2-Glycoprotein I.  We investigated the cytokine production induced by β2-Glycoprotein I in 
activated T cells that infiltrate in vivo atherosclerotic lesions of lupus-antiphospholipid syndrome 
patients. We examined the helper function of β2-Glycoprotein I-specific T cells for the tissue factor 
production, as well as their cytolytic potential and their helper function for antibody production. 
Lupus-antiphospholipid syndrome patients harbor in vivo activated CD4+ T cells that recognize β2-
Glycoprotein I in atherosclerotic lesions. β2-Glycoprotein I induces T cell proliferation and 
expression of both Interleukin-17/Interleukin-21 and Interferon-γ in plaque-derived T cell clones. 
β2-Glycoprotein I-specific T cells display strong help for monocyte tissue factor production, and 
promote antibody production in autologous B cells. Moreover, plaque-derived β2-Glycoprotein I-
specific CD4+ T lymphocytes express both perforin-mediated and Fas/FasLigand-mediated-
cytotoxicity.  Altogether, our results indicate that β2-Glycoprotein I is able to elicit a local 
Interleukin-17/Interleukin-21 and Interferon-γ inflammation in lupus-antiphospholipid syndrome 
patients that might lead, if unabated, to plaque instability and subsequent arterial thrombosis, 
suggesting that the T helper 17/T helper 1 pathway may represent a novel target for the prevention 
and treatment of the disease.       
Keywords 
β2-glycoprotein I, T cell, interferon-gamma, interleukin-17, interleukin-21, tissue factor 
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Introduction 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can be frequently 
associated with antiphospholipid syndrome (APS) characterized by recurrent vascular thrombosis 
and pregnancy morbidities associated with the persistent presence of autoantibodies against 
phospholipid-binding proteins, namely antiphospholipid antibodies (aPL), such as β2-glycoprotein I 
(β2GPI)1.  Besides the role in the acquired pro-coagulant diathesis, aPL have been also associated to 
accelerated atherosclerosis to explain cardiovascular manifestations of the syndrome2-4.  An 
accelerated atherosclerosis in SLE has been initially demonstrated in 1975 by Bulkley et al.5, in a 
necroscopic study, that was further confirmed by Urowitz et al.6. 
Many studies highlighted that SLE is associated with coronary heart disease and aterosclerosis7-9; 
an important prospective study have demonstrated that SLE patients have an accelerated 
progression of carotid plaque formations compare to non lupus controls10.  SLE patients have a 
reduced life expectancy mainly due to increased prevalence of cardiovascular diseases. The major 
cardiovascular events are 2.5 higher in SLE patients compared to the general population. SLE 
women, age range 35-44, in respect to healthy subjects have a 50 times increased risk of myocardial  
infarction and accelerated atherosclerosis, that is a well recognized comorbidity in SLE11,12. 
Atherosclerosis is a multifactorial disease for which a number of different pathogenic mechanisms 
have been proposed. In addition to classical risk factors, in the last two decades the attention has 
been focused on inflammatory processes13,14. Observations in humans and animals suggest that 
atherosclerotic plaques derive from a specific cellular and molecular mechanisms that can be 
ascribed to an inflammatory disease of the arterial wall, the lesions of which consist of activated 
macrophages and T lymphocytes. If inflammation continues unabated, it results in an increased 
number of plaque-infiltrating macrophages and T cells, which contribute to the remodelling of the 
arterial wall, eventually favouring plaque instability and rupture15. Within the T cell population 
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infiltrating the plaque, most cells are activated CD4+ T helper (Th) 1 and Th17 cells expressing 
HLA-DR and the interleukin (IL)-2 receptor (CD25)16,17. 
Current evidence indicates that autoimmunity can be detected within the atherosclerotic lesions18. 
Accordingly, self-phospholipids, such as oxidized low-density lipoprotein (oxLDL) and human heat 
shock proteins drive T cell inflammation in atherosclerotic patients19,20. However, the multifactorial 
nature of atherosclerosis suggests that a larger number of autoantigens might be involved.  
It has been hypothesized that the development of an anti-β2GPI-specific response in the target 
organ may contribute to atherothrombosis in SLE-APS patients. This hypothesis is largely based on 
the β2GPI presence in human atherosclerotic plaques21,22 and on the enhanced fatty streak 
formation in transgenic atherosclerosis-prone mice immunized with β2GPI23,24. Moreover, β2GPI-
reactive T cells have also been found to promote early atherosclerosis in LDL receptor deficient 
mice25.  
In this study we demonstrate that in SLE-APS patients, both IL-17 and IFN-γ are secreted by  
atherosclerotic plaques infiltrating Th cells in response to β2GPI and suggest that β2GPI drives a 
local Th17/Th1 inflammatory response, which can be responsible for plaque instability and rupture, 
leading to atherothrombosis.  
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Methods 
A detailed description of the methods is available in the Online Supplementary Data file. 
Reagents 
  Human β2GPI was purified as described26. We ruled out the presence of contaminants by a 
limulus test. The  human β2GPI used has been tested with a limulus test and resulted negative 
throughout the whole study.  
Patients  
Upon approval of the local Ethical Committee, 10 patients (10 females, mean age 51; range 42-56 
years) with SLE-APS, 10 aPL negative patients (10 females, mean age 51, range 43-55), 5 SLE 
aPL-positive patients (5 females, mean age 49, range 44-53), and 5 SLE aPL-negative patients (5 
females, mean age 50, range 44-56), all affected by carotid atherosclerotic arteriopathy were 
included in the study. The carotid plaques were obtained by endoarterectomy from each patient. The 
clinical informations of each patient are reported in Table S1, S2, S3, and S4. 
All patients studied (SLE-APS, SLE aPL-positive, SLE aPL-negative  and aPL negative 
patients) were eligible for vascular surgery.. All the SLE aPL-positive patients were affected by 
SLE but not by APS, although they were positive for aPL, with serum anti-β2GPI, anti-cardiolipin 
antibodies or with positivity for LA. All SLE aPL-neg patients were affected by SLE but not by 
APS, and they were triple negative for serum aPL, such as anti-β2GPI, anti-cardiolipin antibodies 
and with negativity for Lupus Anticoagulant. 
 
Anti-phospholipid antibody detection 
The detection of aCL and aβ2GPI in patient sera, and analysis of LA was performed as described 
elsewhere28,29.  
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Generation and characterization of T cell clones from atherosclerotic plaques' inflammatory 
infiltrates 
Carotid specimens, obtained by endoarterectomy, were investigated in both SLE-APS and in aPL 
negative patients under the same experimental conditions. Specimens were then disrupted, and 
single T cells were cloned under limiting dilution, as described16. To assess their phenotype profile, 
T cell clones were screened by flow cytometry with fluorochrome-conjugated anti-CD3, anti-CD4, 
anti-CD8 on a BD FACSCanto II (BD Bioscience), using the FACS Diva 6.1.3. software. The 
repertoire of the TCR Vβ chain of β2GPI-specific Th clones was analyzed with a panel of  mAbs 
specific to the following: Vβ1, Vβ2, Vβ4, Vβ5.1, Vβ5.2, Vβ5.3, Vβ7, Vβ8, Vβ9, Vβ11, Vβ12, 
Vβ13.1, Vβ13.2 and Vβ13.6, Vβ14, Vβ16, Vβ17, Vβ18, Vβ20, Vβ21.3, Vβ22, and Vβ23 (Beckman 
Coulter); Vβ6.7 (Gentaur) and Vβ3.1 (In Vitro Gen). Isotype-matched nonspecific Ig were used as 
negative control. Vβ10, Vβ15, and Vβ19  T cell receptor typing were investigated by Clontech kit, 
according to the manufacturer's instructions. Each β2GPI-reactive CD4+ T cell clone was stained by 
only one of the TCR-Vβ chain–specific monoclonal antibodies, showing a single peak of 
fluorescence intensity (Fig. S1) . The cytokine production, the cytotoxicity, the helper functions for 
antibody and tissue factor production of β2GPI-specific T cell clones were performed as 
described16, 30,  31. 
  
Statistical analysis  
Statistical analyses were performed using Student’s t test; data were considered significant if 
p values < 0.05.  
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Results 
Atherosclerotic lesions of SLE-APS patients and SLE aPL-positive patients harbour 
autoreactive β2GPI-specific CD4+ T cell clones.  
Atherosclerotic plaque-infiltrating in vivo activated T cells were expanded in vitro in an 
hrIL-2 conditioned medium, subsequently cloned and studied for their phenotypic and functional 
profile. A total number of 297 CD4+ and 37 CD8+ T cell clones were obtained from atherosclerotic 
lesions of 10 SLE-APS patients. For each patient, CD4+ and CD8+ atherosclerotic lesion-derived T 
cell clones were assayed for proliferation in response to medium, or β2GPI. None of the CD8+ T 
cell clones showed proliferation to β2GPI although they proliferated in response to mitogen 
stimulation (Fig. 1). We have also investigated the amount of β2GPI-specific T cells present in the 
peripheral blood of SLE-APS patients and compared it with the one found in atheromas. The 
proportion of β2GPI-specific CD4+ T cell clones generated from atherosclerotic plaques of SLE-
APS patients was 24%, which is remarkably higher compared with the frequency of β2GPI-specific 
T cells found in the peripheral blood of the same patients (between 1:1900 and 1:3400).  
 
Seventy-one (24%) of the 297 CD4+ T cell clones generated from SLE-APS atherosclerotic 
plaque-infiltrating T cells proliferated significantly to β2GPI (Fig. 1).  Each SLE-APS patient 
displayed a comparable percentage of CD4+ T cell clones responsive to β2GPI (Table S1). On the 
other hand, a total number of 288 CD4+ and 42 CD8+ T cell clones were obtained from 
atherosclerotic lesions of 10 atherotrombotic patients, that were negative for aPL. For each patient, 
CD4+ and CD8+ atherosclerotic lesion-derived T cell clones were assayed for proliferation in 
response to medium or β2GPI. None of the CD4+ or CD8+ T cell clones derived from the 
atherosclerotic lesions showed proliferation to β2GPI (Table S2). A total number of 135 CD4+ and 
21 CD8+ T cell clones were obtained from atherosclerotic lesions of 5 SLE aPL-positive. For each 
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patient, CD4+ and CD8+ atherosclerotic lesion-derived T cell clones were assayed for proliferation 
in response to medium or β2GPI. 25 CD4+ and no CD8+ T cell clones derived from the 
atherosclerotic lesions of SLE aPL-positive patients showed proliferation to β2GPI (Table S3). A 
total number of 136 CD4+ and 30 CD8+ T cell clones were obtained from atherosclerotic lesions of 
5 SLE aPL-negative. For each patient, CD4+ and CD8+ atherosclerotic lesion-derived T cell clones 
were assayed for proliferation in response to medium or β2GPI.  None of the CD4+ or CD8+ T cell 
clones derived from the atherosclerotic lesions showed proliferation to β2GPI (Table S4). 
 
 
All β2GPI-specific T cell clones, both those obtained from the atherosclerotic lesions of SLE-APS 
patients and those obtained from SLE aPL-positive patients, were stimulated with β2GPI and 
autologous APCs. Then, TNF-α and IL-4, IFN-γ and IL-17 production was measured in culture 
supernatants. Upon antigen stimulation with β2GPI of the 71 β2GPI-specific T cell clones obtained 
from SLE-APS patients, 30 were polarized Th1 clones, 10 Th clones were Th17, 27 Th clones were 
Th17/Th1 and only 4 were able to produce IL-4 together with TNF-α (Th0 clones) (Fig. 2).  Upon 
antigen stimulation with β2GPI of the 25 β2GPI-specific T cell clones obtained from SLE aPL-
positive patients, 10 were polarized Th1 clones, 6 Th clones were polarized Th17, 8 Th clones were 
Th17/Th1 and only 1 was Th0  (Fig. 3). T cell blasts from each of the 71 β2GPI-reactive T cell 
clones obtained from atherosclerotic lesions of patients with SLE-APS were further screened by 
IFN-γ and IL-17 ELISPOT in response to β2GPI. Upon appropriate stimulation, 61 atherosclerotic-
derived CD4+ T cell clones produced IFN-γ, and thirty-seven produced IL-17 (Fig. 4). Interestingly, 
all IL-17-producing β2GPI-reactive T cell clones, produce IL-21 (mean±SE, 3.3±0.5 
ng/mL per 106 T cells) in response to antigen stimulation.  
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β2GPI-specific atherosclerotic lesion-infiltrating T cells help monocyte TF production and 
PCA 
Plaque rupture and consequent thrombosis are crucial complications of atherosclerosis. TF 
plays a key role in triggering atherothrombotic events being the primary activator of the coagulation 
cascade. We investigated whether atherosclerotic lesion-infiltrating β2GPI-specific T cells had the 
potential to express helper functions for TF production and PCA by autologous monocytes. 
Antigen-stimulated β2GPI-specific atherosclerotic lesion-derived T cell clones were co-cultured 
with autologous monocytes and levels of TF and PCA were measured. Antigen stimulation resulted 
in the expression of substantial help for TF (Fig. 5A) production and PCA (Fig. 5B) by autologous 
monocytes.  
 
Atherosclerotic lesion-derived β2GPI-specific T cell clones express antigen-dependent help to 
autologous B cells for Ig production 
T-B cell interaction is a multistep process resulting in B cell help depending on the functional 
commitment of the Th cells involved. So far the ability of SLE-APS-derived β2GPI-specific T cell 
clones to provide B cell help for Ig synthesis was investigated. In the absence of the specific 
antigen, no increase in IgM, IgG, or IgA production above spontaneous levels measured in cultures 
containing B cells alone was observed. In the presence of β2GPI and at a T-to-B cell ratio of 0.2 to 
1, all of the β2GPI-specific T cell clones provided substantial help for Ig production. At a 1-to-1 
T/B cell ratio, β2GPI-dependent T cell help for IgM, IgG, and IgA production by B cells was 
remarkably higher (Fig. 6). However, at a 5-to-1 T/B cell ratio, co-culturing B cells with autologous 
β2GPI-specific T cell clones in the presence of β2GPI resulted in a much lower Ig synthesis. 
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Atherosclerotic lesion-derived β2GPI-specific T cell clones display cytotoxic and pro-
apoptotic activity. 
The cytolytic potential of SLE-APS-derived atherosclerotic lesion-derived β2GPI-specific 
autoreactive T cell clones was assessed by using antigen-pulsed 51Cr-labeled autologous EBV-B 
cells as targets. At an E:T ratio of 10:1, all Th1 and Th17/Th1 specific T cell clones were able to 
lyse β2GPI-presenting autologous EBV-B cells (range of specific 51Cr release, 35–65%), whereas 
autologous EBV-B cells pulsed with control ag and co-cultured with the same clones were not lysed 
(Fig. 7A). Likewise 2 Th0 and all Th17 specific T cell clones were able to lyse their target (specific 
51Cr release, 50% and 25-45% respectively), while no lysis was observed when using autologous 
EBV-B cells pulsed with the control ag. 
Fas-FasL mediated apoptosis was assessed using Fas+ Jurkat cells as target. T cell blasts 
from each clone were co-cultured with 51Cr-labeled Jurkat cells at an E:T ratio of 10, 5, and 2.5 to 1 
for 18 h in the presence of PMA and ionomycin (Fig. 7B). Upon mitogen activation, 27 out of 30 
Th1, 24/27 Th17/Th1, 4/10 Th17, and 2 out of 4 Th0 clones were able to induce apoptosis in target 
cells (range of specific 51Cr release, 25-61%). 
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Discussion 
 Several clinical studies and experimental models suggest a role for aPL in 
accelerating atherosclerotic plaque formation in SLE. On the other hand, there is growing evidence 
that aPL represent a risk factor for arterial thrombosis supporting their pathogenic role in 
cardiovascular events1,3,4,32. Here in we report for the first time that a pro-inflammatory and pro-
coagulant β2GPI-specific Th17, Th1 and Th17/Th1 infiltrate in human atherosclerotic lesions of 
patients with SLE-APS and may represent a key pathogenic atherothrombotic mechanism. 
Many self antigens, such as oxLDL, may theoretically be involved in SLE-APS 
atherosclerosis; oxLDL-specific peripheral blood-derived T cells displaying a Th1 profile were 
reported in APS patients33. However, there is no information on whether these cells are actively 
involved in atherosclerotic tissue lesions of SLE-APS patients. In addition, β2GPI was found to 
bind ox-LDL34 raising the issue whether or not the immune response is against ox-LDL or β2GPI 
itself. 
The relevance of the data presented in this paper consists in the demonstration that all ten 
SLE-APS patients with clinically severe atherothrombosis harbored in their target tissues, such as  
atherosclerotic lesions, in vivo-activated CD4+ T cells able to react to β2GPI. CD4+ T cells specific 
for β2GPI were found also in the plaques of SLE aPL-positive patients but not in SLE aPL-negative 
patients nor in atherosclerotic patients without SLE. The results suggested that β2GPI drive 
inflammation in atherosclerotic plaques in SLE-APS and SLE aPL-positive patients, while in SLE 
aPL negative patients and in non SLE patients other antigens are involved in sustaining plaque 
inflammation. With the experimental procedure used in this study, the proportion of β2GPI-specific 
CD4+ T cell clones generated from atherosclerotic plaques of atherotrombotic SLE-APS patients is 
remarkably higher than the frequency of β2GPI-specific T cells found in their peripheral blood. 
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In order to investigate plaque instability we investigated fresh T cells coming from the 
atherosclerotic plaques of SLE-APS patients and we found that plaque-derived CD4+ T cells 
specific produce IFN-γ and IL-17 in response to both β2GPI and to mitogen stimulation. Studying 
at clonal level the β2GPI-specific T cells found in the inflammatory atherosclerotic infiltrates  of 
SLE-APS we found that 42% were polarized T helper 1 cells, 38% were Th17/Th1 cells, 15% were 
polarized Th17 cells, 5% were Th0 cells, and none of T cells were polarized Th2 cells. The lack of 
Th2 cells is an important risk factor in the genesis of atherosclerosis.  T cells indeed play an 
important role in the genesis of atherosclerosis that has been defined a Th1-driven 
immunopathology35,36, and we have demonstrated that Th1 cells, producing high levels of IFN-γ, 
are crucial for the development of the disease16,20,22. Given that atherosclerosis can occur and 
progress even in IFN-γ- or IFN-γR–deficient mice, although with a lower lesion burden37, other Th 
cells and factors are presumably involved in the genesis of the atheroma. A third subset of effector 
Th cells, namely Th17, has been discovered38. Th17 cells are potent inducers of tissue inflammation 
and have been associated with the pathogenesis of many experimental autoimmune diseases and 
human inflammatory conditions39,40. In the lymphocytic infiltrates of SLE-APS atherosclerotic 
plaques, we have found the presence of in vivo-activated plaque-infiltrating T cells able to produce 
IL-17 and IL-21 in response to β2GPI. Among the clonal progeny of T cells infiltrating the lesions, 
we demonstrated the presence of β2GPI -specific T cells able to secrete IL-17. A significant number 
(27%) of IL-17–producing T cells are also IFN-γ producers. This finding is in agreement with a 
previous report that demonstrated the concomitant production of IL-17 and IFN-γ by human 
coronary artery-infiltrating T cells in non SLE patients41-43. Plaque rupture and thrombosis are 
notable complications of atherosclerosis16,43. The methodology used to obtain the plaque derived T-
cells encompasses a clonal expansion step, followed by limiting dilution to obtain single clones. 
The β2GPI-reactive CD4+ T cell clone found in atherosclerotic plaques were unique, based on the 
T-cell receptor - Vβ results obtained in the study. The β2GPI -specific T-cell clones revealed their 
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ability not only to induce macrophage production of TF upon antigen stimulation but also were able 
to promote PCA.  
Th17 cells were shown to play a key role in experimental mouse models of atherosclerosis; 
IL-17 is proatherogenic in experimental model of accelerated atherosclerosis in the presence of high 
fat diet (HFD)44. In fact, in IL-17−/− mice fed with HFD, the aortic lesion size and lipid 
composition as well as macrophage accumulation in the plaques were significantly diminished, and 
the progression of the process was remarkably reduced compared with WT mice. Furthermore IL-
21 was produced by almost all Th1 and Th17/Th1 cells specific for β2GPI. IL-21 is actually up-
regulated in patients with peripheral artery diseases45. Expression of IL-17 in human atherosclerotic 
lesions is associated with increased inflammation and plaque vulnerability and increased Th17 
cells46. An increased incidence of atherosclerosis associated with peripheral blood Th17 responses 
has been demonstrated in patients with SLE47. 
We have demonstrated that β2GPI was able to activate Th17 and Th1 responses in 
atherosclerotic lesions of SLE-APS patients. The relevance of Th17/Th1 cells in non SLE-
atherosclerosis patients have been demonstrated in other studies48,49, suggesting that Th1 and Th17 
cells might plastically shift one into the other in different phases of the disease. It has been shown 
that Th17 cells might shift towards Th1 but not to Th2 via IL-12 receptor signalling50.  
Overall, our findings support the concept that a crucial component of atherosclerosis in 
SLE-APS is represented by T-cell–mediated immunity and that chronic Th response against β2GPI  
plays an important role in the genesis of atheroma in SLE-APS patients51.  Among β2GPI-specific 
IL-17–producing Th cells, the majority were polarized Th17 cells, whereas others were able to 
produce both IFN-γ and IL-17. Thus, it is possible to speculate that Th17 and Th1 cells co-migrate 
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to the inflamed tissue and cooperate in the ongoing inflammatory process within the atherosclerotic 
lesion16,17,39,52.  
In addition, upon appropriate Ag stimulation, the majority of atherosclerotic plaque-derived 
β2GPI-specific clones induced both perforin-mediated cytolysis and Fas/FasL-mediated apoptosis 
in target cells and were able to drive the up-regulation of TF production by monocytes within 
atherosclerotic plaques, thus further contributing to the thrombogenicity of lesions42,43,53. Our 
results demonstrate that β2GPI is a major factor able to drive Th17 and Th1 inflammatory process 
in SLE-APS atherosclerosis and suggest that Th17/Th1 cell pathway and β2GPI may represent 
important targets for the prevention and treatment of the disease.  
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Figure legends 
Figure 1. Antigen specificity of atherosclerotic plaque CD4+ T and CD8+ T cell clones obtained 
from SLE-APS patients. Both CD4+ T and CD8+ T cell clones were tested for antigen-specificity. 
T cell clones were analyzed for their responsiveness to β2GPI (10 nM) ( ), or medium () by 
measuring [3H]thymidine uptake after 60 h of co-culture with irradiated autologous PBMCs.  71 out 
of 297 CD4+ T cell clones proliferated in response to β2GPI and are shown in panel A. None of the 
37 CD8+ T cell clone proliferated to β2GPI (panel B). 
 
Figure 2. Cytokine profile of atherosclerotic plaque β2GPI-specific CD4+ T cell clones 
obtained from SLE-APS patients. Th clones were tested for cytokine production (A-B). β2GPI-
specific Th clones were stimulated with β2GPI and TNF-α and IL-4, IFN-γ and IL-17 production 
was measured in culture supernatants. In unstimulated cultures, levels of TNF-α, IL-4, IFN-γ and 
IL-17 were consistently < 20 pg/ml. CD4+ T cell clones producing IFN-γ, but not IL-17 nor IL-4 
were coded as Th1. CD4+ T cell clones producing IL-17, but not IFN-γ nor IL-4 were coded as 
Th17. CD4+ T cell clones producing IFN-γ, and IL-17, but not IL-4 were coded as Th17/Th1. CD4+ 
T cell clones producing TNF-α and IL-4, but not IL-17 were coded as Th0. 
 
Figure 3. Cytokine profile of atherosclerotic plaque β2GPI-specific CD4+ T cell clones 
obtained from SLE-aPL-positive patients. Th clones were tested for cytokine production (A-B). 
β2GPI-specific Th clones were stimulated with β2GPI and TNF-α and IL-4, IFN-γ and IL-17 
production was measured in culture supernatants. In unstimulated cultures, levels of TNF-α, IL-4, 
IFN-γ and IL-17 were consistently < 20 pg/ml. CD4+ T cell clones producing IFN-γ, but not IL-17 
nor IL-4 were coded as Th1. CD4+ T cell clones producing IL-17, but not IFN-γ nor IL-4 were 
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coded as Th17. CD4+ T cell clones producing IFN-γ, and IL-17, but not IL-4 were coded as 
Th17/Th1. CD4+ T cell clones producing TNF-α and IL-4, but not IL-17 were coded as Th0. 
 
 
Figure 4. β2GPI driven IFN-γ and IL-17 secretion by β2GPI-specific atherosclerotic plaque 
derived Th clones from SLE-APS patients. Numbers of IFN-γ spot-forming cells (SFCs) after 
stimulation of atherosclerotic plaque derived T cell clones with medium alone, or β2GPI (A). T cell 
blasts from each clone were stimulated for 48 h with medium alone (), or β2GPI ( ), in the 
presence of irradiated autologous APCs in ELISPOT microplates coated with anti-IFN-γ antibody. 
IFN-γ SFCs were then counted by using an automated reader. After specific stimulation, 61/71 
β2GPI-specific atherosclerotic plaque-derived T cell clones produced IFN-γ. Values are the mean ± 
SD number of SFCs per 105 cultured cells over background levels.  
Numbers of IL-17 spot-forming cells SFCs after stimulation of atherosclerotic plaque derived T cell 
clones with medium alone, or β2GPI (B). T cell blasts from each clone were stimulated for 48 h 
with medium alone (), or β2GPI ( ) in the presence of irradiated autologous APCs in ELISPOT 
microplates coated with anti-IL-17 antibody. IL-17 SFCs were then counted by using an automated 
reader. After specific stimulation 37/71 β2GPI-specific atherosclerotic plaque-derived T cell clones 
produced IL-17. Values are the mean ± SD number of SFCs per 105 cultured cells over background 
levels. 
 
Figure 5. Induction of TF synthesis and PCA by atherosclerotic plaque β2GPI-specific T cells 
derived from SLE-APS patients. Atherosclerotic plaque β2GPI-specific T cells induce TF 
production and PCA by autologous monocytes. To assess their ability to induce TF production and 
PCA by autologous monocytes, β2GPI-specific Th clones were co-cultured with autologous 
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monocytes in the presence of medium () or β2GPI ( ) (A). TF production by monocytes was 
assessed by ELISA. The results shown represent TF levels induced by T cell clones over the TF 
production in cultures of monocytes alone. Atherosclerotic plaque-derived β2GPI-specific T cell 
induced PCA in autologous monocytes (B). β2GPI-specific Th clones were co-cultured with 
autologous monocytes in the presence of medium () or β2GPI ( ). At the end of the culture 
period, cells were disrupted and total PCA was quantitated as reported in Materials and Methods. 
The results shown represent PCA induced by T cell clones in monocytes over the PCA in cultures 
of monocytes alone. 
 
Figure 6. Helper function of atherosclerotic plaque β2GPI-specific T cells derived from SLE-
APS patients. Autologous peripheral blood B cells (5 x 104) were co-cultured with β2GPI-specific 
T cell blasts at a T:B ratio of 0.2, 1, and 5 to 1 in the absence () or presence of β2GPI ( ). After 
10 days, culture supernatants were harvested and tested for the presence of IgM, IgG, and IgA by 
ELISA. Results represent the mean value (+/–SE) of Ig levels induced by T cell clones compared to 
the Ig spontaneous production in B cell cultures alone. 
 
Figure 7. Cytotoxic and pro-apoptotic activity of β2GPI-specific atherosclerotic plaque-
derived CD4+ T cells derived from SLE-APS patients. (A) To assess their cytotoxicity, β2GPI-
specific CD4+ T cell clones were co-cultured at different E:T ratios with 51Cr-labeled autologous 
EBV-B cells pulsed with β2GPI ( ) or medium alone (). 51Cr release was measured as index of 
specific target cell lysis. (B) To assess their ability to induce apoptosis in target cells, β2GPI-
specific CD4+ T cell clones stimulated with mitogen ( ) or medium alone () were co-cultured 
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with 51Cr-labeled Fas+Jurkat cells, and 51Cr release was measured as the index of apoptotic target 
cell death.  
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Supplemental Methods 
 
Reagents 
  Human β2GPI was purified by perchloric acid treatment of pooled normal human sera 
obtained from blood donors followed by affinity purification on Heparin column (HiTrap Heparin 
HP, GE Healthcare, Milan, Italy) and by ion-exchange chromatography (Resource-S, GE 
Healthcare)1. We also ruled out the presence of contaminants by a limulus test. The  human β2GPI 
used has been tested with a limulus test and resulted negative throughout the whole study. Human 
recombinant (hr) interleukin (IL)-2 and tetanus toxoid (TT) were provided by Novartis, Siena, Italy. 
PHA was purchased from Life Technologies (Carlsbad, CA).  Fluorochrome-conjugated human 
monoclonal antibodies (mAbs) anti-CD3, anti-CD4, anti-CD8, anti-IFNand isotype-matched 
control mAb were purchased from BD Biosciences (San Jose, CA, USA). The fluorochrome-
conjugated anti-IL-17 mAb was obtained from eBioscience (San Diego, CA, USA). PMA, ionomycin 
and brefeldin A were purchased from BD Biosciences (San Jose, CA, USA).  
 
Patients  
Upon approval of the local Ethical Committee, 10 patients (10 females, mean age 51; range 42-56 
years) with SLE-APS, 10 aPL negative patients (10 females, mean age 51, range 43-55), 5 SLE aPL-
positive patients (5 females, mean age 49, range 44-53), and 5 SLE aPL-negative patients (5 females, 
mean age 50, range 44-56), all affected by carotid atherosclerotic arteriopathy were included in the 
study. The carotid plaques were obtained by endoarterectomy from each patient. The clinical 
informations of each patient are reported in Table S1, S2, S3, and S4. 
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All patients studied (SLE-APS, SLE aPL-positive, SLE aPL-negative  and aPL negative 
patients) were eligible for vascular surgery. SLE-APS patients were triple positive for aPL, with high 
titers serum anti-2GPI, anti-cardiolipin (aCL) antibodies and with positivity for Lupus 
Anticoagulant (LA). All SLE-APS patients in this study satisfied the Myiakis’s criteria for APS, and 
they were on oral anticoagulation with vitamin K antagonists, then switched to low molecular weight 
heparin few days before surgery2. None of them displayed traditional risk factors for atherosclerosis 
and they were not receiving any anti-lipidemic drugs. All the SLE aPL-positive patients were affected 
by SLE but not by APS, although they were positive for aPL, with serum anti-2GPI, anti-cardiolipin 
antibodies or with positivity for LA. All SLE aPL-neg patients were affected by SLE but not by APS, 
and they were triple negative for serum aPL, such as anti-2GPI, anti-cardiolipin antibodies and with 
negativity for Lupus Anticoagulant. 
 
Anti-phospholipid antibody detection 
For the detection of aCL and a2GPI in patient sera, commercially available solid-phase ELISA 
employing purified human 2GPI in complex with CL and human 2GPI were used (Inova, Ca, 
USA). Sera were considered positive when their concentration exceeded the cut-off of 10 U/mL for 
IgG and IgM. All samples were tested by the respective in-house assay as described elsewhere3. The 
results of the two techniques were comparable. 
Analysis of LA was performed in accordance with the international recommendations as 
described recently4.  
 
Generation and characterization of T cell clones from atherosclerotic plaques' inflammatory 
infiltrates 
3 
 
Carotid specimens, obtained by endoarterectomy, were investigated in both SLE-APS and in aPL 
negative patients under the same experimental conditions. Plaque fragments were cultured for 7 days 
in RPMI 1640 medium supplemented with IL-2 (50 units/ml) to expand in vivo-activated T cells. 
Specimens were then disrupted, and single T cells were cloned under limiting dilution, as described5. 
To assess their phenotype profile, T cell clones were screened by flow cytometry with fluorochrome-
conjugated anti-CD3, anti-CD4, anti-CD8 on a BD FACSCanto II (BD Bioscience), using the FACS 
Diva 6.1.3. software. The repertoire of the TCR Vβ chain of 2GPI-specific Th clones was analyzed 
with a panel of  mAbs specific to the following: Vβ1, Vβ2, Vβ4, Vβ5.1, Vβ5.2, Vβ5.3, Vβ7, Vβ8, 
Vβ9, Vβ11, Vβ12, Vβ13.1, Vβ13.2 and Vβ13.6, Vβ14, Vβ16, Vβ17, Vβ18, Vβ20, Vβ21.3, Vβ22, 
and Vβ23 (Beckman Coulter); Vβ6.7 (Gentaur) and Vβ3.1 (In Vitro Gen). Isotype-matched 
nonspecific Ig were used as negative control. Vβ10, Vβ15, and Vβ19  T cell receptor typing were 
investigated by Clontech kit, according to the manufacturer's instructions. Each 2GPI-reactive CD4 
T cell clone was stained by only one of the TCR-Vβ chain–specific monoclonal antibodies, showing 
a single peak of fluorescence intensity (Fig. S1) . 
T cell clones were then analyzed for their responsiveness to 2GPI by measuring [3H]thymidine 
uptake after 60 h of co-culture with irradiated autologous PBMCs in the presence of medium, or 
2GPI (10 nM). The mitogenic index (MI) was calculated as the ratio between mean values of counts 
per minute (cpm) obtained in stimulated cultures and those obtained in the presence of medium alone. 
MI >5 was considered as positive.  
 
Assessment of T cell clones cytokine profile. 
  To assess the cytokine production of 2GPI-specific T cell clones upon antigen stimulation, 
5 × 105 T cell blasts of each clone were co-cultured for 48 h in 0.5 ml of serum-free medium with 5 
× 105 irradiated autologous PBMCs in the absence or presence of 2GPI (10 nM). At the end of the 
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culture period, duplicate samples of each supernatant were assayed for their IFN-γ, TNF-α, IL-4, IL-
21 and IL-17 (BioSource International, Camarillo, CA) production by ELISA5. For further 
investigation, T cell blasts from each 2GPI-specific T cell clone were stimulated with medium or 
2GPI (10 nM) in the presence of autologous APCs for 48 h in ELISPOT microplates coated with 
anti-IFN- or anti-IL-17 antibody, respectively (eBioscience, Inc., San Diego, Ca, USA). At the end 
of culture period, the number of IFN- and IL-17 SFCs were counted as described5. 
 
T cell clone-mediated cytotoxicity and Fas-Fas Ligand (L) mediated proapoptotic activity. 
  T cell clones cytolytic activity was assessed as reported5. T cell blasts of 2GPI-specific T 
cell clones were incubated at ratios of 10, 5, and 2.5 to 1 with 51Cr-labeled autologous Epstein-Barr 
virus transformed (EBV)-B cells pre-incubated with 2GPI (10 nM) or medium alone. After 
centrifugation, microplates were incubated for 8 h at 37° C, and 0.1 ml of supernatant was removed 
for the measurement of 51Cr release, as reported16. The ability of 2GPI-specific T cell clones to 
induce Fas-FasL mediated apoptosis was assessed using Fas+ Jurkat cells as target. T cell blasts from 
each clone were co-cultured with 51Cr-labeled Jurkat cells at an effector/target (E:T) ratio of 10, 5, 
and 2.5 to 1 for 18 h in the presence of PMA (10 ng/ml) and ionomycin (1 mol/ml), as reported5.  
 
T helper assay to assess their ability to induce Tissue Factor (TF) production and procoagulant 
activity (PCA) in autologus monocytes. 
  T cell blasts (8 × 105 / ml) of 2GPI-specific T cell clones were co-cultured for 16 hrs with 
autologous monocytes (4 × 105 / ml) in the presence of serum-free medium or 2GPI (10 nM). At the 
end of the culture period, the amount of TF protein was quantitated by a specific ELISA (American 
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Diagnostica, Greenwich, CT) in duplicate samples of supernatants obtained from cell suspensions 
after solubilization of membrane proteins with Triton X-100 and ultracentrifugation, as reported5. At 
the end of culture period, cell suspensions consisting of monocytes alone, or monocytes plus activated 
T cells were disrupted by repeated freezing and thawing followed by sonication. Total cellular content 
of PCA was determined in a one-stage clotting assay and expressed in arbitrary units (U/105 
monocytes) assigned by comparison with a standard curve derived from rabbit brain thromboplastin 
standard (Manchester Comparative Reagents, Manchester, UK), as reported5. Our log-log plot was 
linear up to 200 seconds clotting time. Values less than 10 U/105 monocytes corresponded to clotting 
times ranging from 170 to 80 seconds. One thousand units corresponded to approximately 22 seconds 
clotting time. PCA was characterized as factor VII-dependent procoagulant activity by evaluating its 
sensitivity to phospholipase C (Calbiochem, San Diego, CA), concanavalin A, and cysteine protease 
inhibitor (HgCI2), and by using factor VII- and factor X-deficient plasma samples6. 
 
T cell clones' helper assay to evaluate the induction of immunoglobulin (Ig) production by 
autologous B cell  
T cell blasts of each clone were co-cultured at ratios of 0.2, 1, and 5 to 1 with autologous 
PBMCs in the absence or presence of β2GPI and, on day 10, IgM, IgG, and IgA levels in cell free 
culture supernatants were measured as previously described7. 
  
Statistical analysis  
Statistical analyses were performed using Student’s t test; data were considered significant if 
p values > 0.05.  
Study approval 
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Prior written informed consent was received from SLE patients and controls according to the Helsinki 
Declaration. Experiments were approved by the local Ethics Committee.  
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Legends to Supplementary figures 
Figure S1. TCR V chain repertoire of 2GPI-specific T cell clones derived from the 
atherosclerotique plaques of SLE-APS patients. The cloality of T cell clones specific for 2GPI 
was analysed by a panel of monoclonal antibodies specific for human TCR V families, as detailed 
in Material and Methods. T cell blasts from each clone were divided in aliquots and stained with each 
of the monolonaly antibody and the appropriate controls. All clones obtained from two representative 
patients, named “A” and “B”, are represented in the figure. 
Figure S2. IFN- and IL-17 intra-cellular cytokine staining of plaque-infiltrating T cells of SLE-
APS patients. Cells were stained for surface and intracellular markers with the following mAbs for 
flow cytometry: anti-CD4-PerCP, anti-IL-17-PE, and anti-IFN--FITC (Becton Dickinson). Samples 
obtained from the atherosclerotic lesions of each of the SLE-APS patients were stimulated with PMA 
(25 ng/ml) plus 1 g/ml ionomycin in the presence of brefeldin A (1 g/ml). The analysis was 
performed using FACS Canto II (BD), by the acquisition software FACSDiva 6.1.3. For each sample 
5000 events were acquired. Dot plots expression of IFN-+ and IL-17+ on CD4+ T cells of the 10 T-
cell lines obtained from the 10 SLE-APS patients (named A, B, C, D, E, F, G, H, I, L) are shown. 
Figure S3. 2GPI driven IFN- and IL-17 secretion by 2GPI-specific atherosclerotic plaque 
derived T-cells from SLE-APS patients. Atherosclerotic plaque-derived T-cell lines were expanded 
from SLE-APS patients by addition of IL-2. At day 7, T-cell blasts from each line were stimulated 
for 48 h with 2GPI or medium, in the presence of irradiated autologous APCs in ELISPOT 
microplates coated with anti-IFN-anti-IL-17, or anti-IL-4  antibodies. After specific stimulation 
with 2GPI, a significant proportion of SLE-APS atherosclerotic plaque-derived Th cells produced 
IL-17 and IFN-, but not IL-4. Values are the mean ± SD number of SFCs per 105 cells over 
background levels. 
 Patients Age Sex Treatment SLEDAI Autoantibodies Total clones 
Total No. of 
CD8+ 
clones 
No. of 
CD8+ 
clones 
reactive to 
β2GPI 
Total No. of 
CD4+ 
clones 
No. of 
CD4+ 
clones 
reactive to 
β2GPI 
 A 42 F a+b 7 c+d+e 38 5 0 33 8 
 B 56 F a+b 8 c+d+e+f 34 4 0 30 6 
 C 51 F b 7 c+d 33 6 0 27 6 
 D 50 F b 5 e 31 1 0 30 8 
 E 50 F b 8 c+d+e 32 4 0 28 7 
 F 54 F a+b 6 c+d+g 34 3 0 31 7 
 G 55 F b 7 c+d-h 35 3 0 32 8 
 H 48 F a+b 7 c+d+e 30 3 0 27 7 
 I 49 F b 8 c+d+e+h 36 4 0 32 8 
 L 55 F a+b 6 c+d 31 4 0 27 6 
 
Table S1. Clinical and lab information of the 10 SLE-APS patients. All the 10 patients shown in this table were affected by SLE-APS and were 
triple positive for aPL, with high titers serum anti-2GPI, anti-cardiolipin antibodies and with positivity for Lupus Anticoagulant. a: treated with 
hydroxychloroquine; b: treated with glucocorticoids; c: ANA-positive; d: anti-SSA-positive; e: anti-ds DNA-positive; f: anti-SSB-positive; g: anti-
U1 RNP-positive; h: anti-Sm-positive. 
 
 Patients Age Sex Treatment SLEDAI Autoantibodies Total clones 
Total No. of 
CD8+ 
clones 
No. of 
CD8+ 
clones 
reactive to 
β2GPI 
Total No. of 
CD4+ 
clones 
No. of 
CD4+ 
clones 
reactive to 
β2GPI 
 M 43 F none 0 none 39 5 0 36 0 
 N 55 F none 0 none 37 4 0 33 0 
 O 51 F none 0 none 29 7 0 22 0 
 P 50 F none 0 none 28 4 0 24 0 
 Q 50 F none 0 none 36 4 0 32 0 
 R 54 F none 0 none 31 3 0 28 0 
 S 55 F none 0 none 38 5 0 33 0 
 T 48 F none 0 none 26 3 0 23 0 
 U 49 F none 0 none 34 5 0 27 0 
 V 55 F none 0 none 32 2 0 30 0 
 
Table S2. Clinical and lab information of the 10 aPL-neg patients. All the 10 patients shown in this table were affected by carotid atherosclerotic 
arteriopathy but not by SLE-APS and were triple negative for serum aPL, such as anti-2GPI, anti-cardiolipin antibodies and with negativity for 
Lupus Anticoagulant, and they were all negative for any autoantibody.They were not treated with any steroids, nor other immune-suppressants. 
 
  
 
       
Patients Age Sex Treatment SLEDAI Autoantibodies Total clones 
Total No. of 
CD8+ 
clones 
No. of 
CD8+ 
clones 
reactive to 
β2GPI 
Total No. of 
CD4+ 
clones 
No. of 
CD4+ 
clones 
reactive to 
β2GPI 
Y 44 F a+b 6 c+d 32 4 0 28 4 
 YA 53 F b 9 c+e 28 3 0 24 3 
 YB 52 F b 8 c+d+e 25 5 0 20 5 
 YC 48 F a+b 7 c+d 34 3 0 31 6 
 YD 49 F a+b 5 c+d+e+f 38 6 0 32 7 
 
Table S3. Clinical and lab information of the 5 SLE aPL-pos patients. All the 5 patients shown in this table were affected by SLE but not by 
APS, although they were positive for aPL, with serum anti-2GPI, anti-cardiolipin antibodies or with positivity for Lupus Anticoagulant. a: treated 
with hydroxychloroquine; b: treated with glucocorticoids; c: ANA-positive; d: anti-SSA-positive; e: anti-ds DNA-positive; f: anti-SSB-positive; g: 
anti-U1 RNP-positive; h: anti-Sm-positive. 
 
 
 
  
 
 
 
 
Patients Age Sex Treatment SLEDAI Autoantibodies Total clones 
Total No. of 
CD8+ 
clones 
No. of 
CD8+ 
clones 
reactive to 
β2GPI 
Total No. of 
CD4+ 
clones 
No. of 
CD4+ 
clones 
reactive to 
β2GPI 
Z 52 F b 7 c+d+e 29 5 0 26 0 
 ZA 49 F a+b 9 c+e+g 34 4 0 28 0 
 ZB 51 F a+b 8 c+e+h 31 7 0 24 0 
 ZC 44 F b 6 c+h+g 39 6 0 33 0 
 ZD 56 F b 7 c+e+h 33 8 0 25 0 
 
Table S4. Clinical and lab information of the 5 SLE aPL-neg patients. All the 5 patients shown in this table were affected by SLE but not by 
APS, and they were triple negative for serum aPL, such as anti-2GPI, anti-cardiolipin antibodies and with negativity for Lupus Anticoagulant. a: 
treated with hydroxychloroquine; b: treated with glucocorticoids; c: ANA-positive; d: anti-SSA-positive; e: anti-ds DNA-positive; f: anti-SSB-
positive; g: anti-U1 RNP-positive; h: anti-Sm-positive. 
 
              
 

